Create and Use Synergies

Under the direction of Prof. Dr. Oliver Kappe, CCFLOW develops and researches innovative and novel methods for the continuous manufacture of active pharmaceutical ingredients. Through the developments of both technologies and processes the production of medicines can be regionalized, creating the possibility to locate the manufacture in places of great need and also be produced more sustainably, minimizing the impact on the environment and rationalizing the need of resources.

In direct and close collaboration with 15 international industry partners and two scientific partners, the RCPE and CC FLOW connects decision makers and knowledge creators and enables the transformation of pharmaceutical manufacture. “Within our role as a competence centre, connecting industry and science/academia has always been one of our major goals. Only when knowledge meets the will for implementation, sustainable value can be created.”, said Dr. Thomas Klein, Business Director RCPE.

Even after a decade, the development of the RCPE continues. Through CCFLOW the centre can now connect primary and secondary manufacture, allowing to holistically research medicines of the future. “The development of drugs is essentially a time and cost intensive process”, states Prof. Dr. Johannes Khinast, Scientific Director RCPE, “With CCFLOW and therefore the increased competences and expanded portfolio we can accelerate this process while ensuring better quality products for patients.”

Internationally Acknowledged

This competence attracts interest from all over the world. Through their involvement and commitment in the Medicines for All Institute, Microsoft Founder Bill Gates and his wife Melinda support CCFLOW through their Bill & Melinda Gates Foundation. The major goal of the institute, located at the Virginia Commonwealth University in Richmond, USA is to create more affordable medicines as on third of the
world’s population still doesn’t have access to health care and life saving medication. As part of a selected group of collaborators, the research team around Prof. Dr. Kappe will be working more effective and generally affordable processes. “Continuous processes can revolutionize the conditions for synthesis of pharmaceutical agents”, claims Kappe. Within the next five years, students and other researchers will focus on new processes for HIV/AIDS medication.

With its research RCPE & CCFLOW contribute to an efficient and more capable health care, nationally and internationally. Through the research at the main location in Graz, researchers from 24 nations ensure that novel and life-saving molecules arrive where they are need most: with the patient.

Through the implementation of technology, continuous process and methodologies developed at RCPE, lead times can be decreased, unnecessary process steps be can be eliminated and process can be holistically optimized – creating competitive advantages for pharmaceutical companies and contract manufacturers. Additionally the long-term funding and support of RCPE and CCFLOW is crucial towards the recruitment and maintenance of key staff and also enabling perfect training and education conditions for students.

---

**Contact and information**

**K1-Centre**

Research Center Pharmaceutical Engineering GmbH
Inffeldgasse 13, 8010 Graz, Austria
T +43 (0) 316 873 30940
E thomas.klein@rcpe.at, www.rcpe.at

**Project coordinator**
Dr. Thomas Klein

**Project partners**

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anton Paar GmbH</td>
<td>Austria</td>
</tr>
<tr>
<td>AstraZeneca UK Limited</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Lilly Spain S.A.</td>
<td>Spain</td>
</tr>
<tr>
<td>Lonza Ltd.</td>
<td>Switzerland</td>
</tr>
<tr>
<td>UCB Pharma S.A. Belgium</td>
<td>Belgium</td>
</tr>
</tbody>
</table>

---

This success story was provided by the consortium leader/centre management for the purpose of being published on the FFG website. FFG does not take responsibility for the accuracy, completeness and the currentness of the information stated.